Idiopathic pulmonary fibrosis

Current Opinion in Pulmonary Medicine

Volumn 2, Issue 5, 1996, Pages 343-346

  Sharma, Om P ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; EDITORIAL; FEMALE; HUMAN; IMMUNOLOGY; LUNG FIBROSIS; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY FIBROSIS;

EID: 0030224927     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199609000-00001     Document Type: Review

References (39)

1. Sharma OP: Interstitial Lung disease. Curr Opin Pulm Med 1995, 1:345-350.
2. Donnelly S, Strieter R, Kunkel S: Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993, 341:643-647.
3. Fujimoto K, Kubo K, Yamaguchi S, Honda T, Matsuzawa Y: Eosinophil activation in patients with pulmonary fibrosis. Chest 1995, 108:48-54.
4. Cambrey AD, Harrison NK, Dawes KE, et al.: Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 1994, 11:439-445.
5. Gauldie J, Jordana M, Cox G: Cytokines and pulmonary fibrosis. Thorax 1993, 48:931-935.
6. Tetley T: Proteinase imbalance, its role in lung disease. Thorax 1993, 48:560-565.
7. Hernandez-Rodriguez N, Cambrey A, Harrison N, Chambers R, Gray A, Southcott A, duBois R, et al.: Role of thrombin in pulmonary fibrosis. Lancet 1995, 346:1071-1073.
8. Cross C, Van der Vliet A, O'Neill C, Louie S, Hall B: Oxidants, antioxidants, and respiratory tract lining fluids. Environ Health Perspect 1994, 102:(suppl10):185-191.
9. duBois R: Idiopathic pulmonary fibrosis. Annu Rev Med 1993, 44:441-450.
10. Tetley T, Rogers D: Development of new treatment for lung disease. Respir Med 1996, 30:5-23.
11. Kanematsu T, Kitaichi M, Nishimura K, Nagai S, Izumi T: Clubbing of the fingers and smooth muscle proliferation in fibrotic changes in the lung in patients with idiopathic pulmonary fibrosis. Chest 1994, 105:339-342.
12. Turner-Warwick M, Burrows B, Johnson B: Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1980, 35:593-599.
13. Winterbaur R, Hammer S, Hallman K, Hayes J, Pardee N, Morgan E, et al.: Diffuse interstitial pneumonitis: clinicopathologic correlation in 20 patients treated with prednisone/azathioprine. Am J Med 1978, 65:661-672.
14. Johnston M, Kwan S, Snell S: Randomized control trial comparing prednisolone alone with cyclophosphamide and low dose prednisone in cryptogenic fibrosing alveolitis. Thorax 1989, 44:280-288.
15. Meir-sydoio J, Rust M, Dronenberger H, Theil C, Amthor M, Riemann H: Long term follow-up of lung function parameters in patients with idiopathic pulmonary fibrosis treated with prednisone and azathioprine or d-penicillamine. Prax Klin Pneumol 1979, 33:680-688.
16. Moolman J, Bardin P, Possoum D, Jobert J: Cyclosporine as a treatment for interstitial lung disease of unknown etiology. Thorax 1991, 46:592-595.
17. Schwartz D, Helmers R, Galvin J, van Fossen D, Frees K, Dayton C, et al.: Determinants of survival in idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 1994, 149:445-454.
18. Hunninghake G, Kalica R: Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995, 151:915-918. An excellent review of the topic.
19. Phan SH: New strategies for treatment of pulmonary fibrosis. Thorax 1995, 50:415-444. An outstanding review of the immunopathogenesis of pulmonary fibrosis and various treatment options directed to major cytokines, chemokines, oxidants and other steps of the inflammatory cycle.
20. Wherry J, Pennington J, Wenzel R: Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med 1993, 10(suppl):S436-S440.
21. Maini R, Brennan F, Williams R, Chu C, Cope A, Gibbons D, et al.: TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. Clin Exp Rheumatol 1993, 11(suppl 8):173-175.
22. Mohler K, Torrance D, Smith C, Goodwin R, Stremler K, Fung V, et al.: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and antagonists. J Immunol 1993, 151:1548-1561.
23. Corrin B, Butcher D, McAnulty R, et al.: Immunohistochemical localization of transforming growth factor β1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994, 24:145-150.
24. Giri S, Hyde D, Hollinger M: Effect of antibody to transforming growth factor β on bleomycin Induced accumulation of lung collagen in mice. Thorax 1993, 48:959-966.
25. Border W, Noble N, Yamamoto T, Tomooka S, Kagami S: Antagonists of transforming growth factor β: a novel approach to treatment of glomerulonephritis and prevention of glomerulosclerosis. Kidney Int 1992, 41:566-570.
26. Massague J: Receptors for the TGF-beta family. Cell 1992, 69:1067-1070.
27. Shahzeidi S, Sarnstrand B, Jeffery P, McAnulty R, Laurent G: Oral N-acetylcysteine reduces bleomycin induced collagen deposition in the lungs of mice. Eur Respir J 1991, 4:845-852.
28. Wang Q, Giri S, Hyde D, Li C: Amelioration of bleomycin induced fibrosis in hamsters by combined treatment of taurine and niacin. Biochem Pharmacol 1991, 92:1115-1122.
29. Meyer A, Buhl R, Magnussen H: The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994, 7:431-436.
30. Borok Z, Buhl R, Grimes G, Bokser A, Hubbard R, Halroyd K, et al.: Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991, 338:215-216.
31. Giri S, Hyde D: Ameliorating effect of an interferon inducer polyionosinic-polycytidylic acid on bleomycin-induced lung fibrosis in hamsters: morphologic and biologic evidence. Am J Pathol 1988, 133:525-536.
32. Hein R, Behr J, Hundgen M, Hunzelman N, Meurer M, Braun-Falco O, et al.: Treatment of systemic sclerosis with gamma interferon. Br J Dermatol 1992, 126:496-501.
33. Phan S, Gannon D, Ward P, Karmiol S: Mechanism of neutrophil-induced xanthine dehydrogenase to xanthine oxidase conversion in endothelial cells: evidence of a role for elastase. Am J Respir Cell Mol Biol 1992, 6:270-278.
34. Piguet P, Rosen H, Vesin C, Grau G: Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with ant CD-11 antibodies. Am Rev Respir Dis 1993, 147:435-441.
35. Ward W, Molteni A, Tsao C, Kim Y, Hinz J: Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 1992, 22:623-625.
36. Goldstein R, Fine A: Potential therapeutic initiative for fibrogenic lung disease. Chest 1995, 108:858-860.
37. MacNee I, Rahman I: Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 1995, 50(suppl 1):553-558.
38. Schwarz M: Treatment of IPF: What does the future hold? Chest 1995, 108:601-602. A thought-provoking, succinct editorial.
39. Bitternian P, Polonovsky V, Ingbar D: Repair after acute lung injury. Chest 1994, 105(suppl):1185-12115.